KRRO
NASDAQ HealthcareKorro Bio, Inc. - Common Stock
Biotechnology
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
๐ Market Data
| Price | $11.00 |
|---|---|
| Volume | 156,583 |
| Market Cap | 158.65M |
| Beta | 2.230 |
| RSI (14-Day) | 48.8 |
| 200-Day MA | $18.29 |
| 50-Day MA | $12.40 |
| 52-Week High | $55.89 |
| 52-Week Low | $5.20 |
| Forward P/E | -2.18 |
| Price / Book | 1.33 |
๐ฏ Investment Strategy Scores
KRRO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (96/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find KRRO in your text
Paste any article, transcript, or post โ the tool will extract KRRO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.